The New York Times (8/4, A1, Belluck) reported the FDA has approved Zurzuvae (zuranolone), “the first pill for postpartum depression, a milestone considered likely to increase recognition and treatment of” the condition. According to the Times, “Clinical trial data show the pill works quickly, beginning to ease depression in as little as three days, significantly faster than general antidepressants, which can take two weeks or longer to have an effect.”

NBC News (8/4, Bendix, Kopf) reported, “The medication…is taken daily for two weeks.” Researchers found, “in a pair of clinical trials involving women who experienced severe depression after having a baby, the drug improved symptoms – such as anxiety, difficulty sleeping, loss of pleasure, low energy, guilt or social withdrawal – as early as three days after taking the first pill.”

Also covering the story were CNN (8/4, Howard), Reuters (8/5), The Hill (8/4, Robertson), the AP (8/4, Perrone), HealthDay (8/5, Mann), MedPage Today (8/4, Monaco), and Medscape (8/4, Marcus, Subscription Publication).

Related Links:

— “FDA approves first pill for postpartum depression,”Aria Bendix and Marina Kopf, NBC News, August 4, 2023

According to Healio (8/3, Herpen), “rates of new-onset mental health conditions were higher in U.S. soldiers with a history of military-related traumatic brain injury” (TBI), “while increased risk for suicide was both directly and indirectly associated with TBI history.” Investigators arrived at this conclusion after having examined data on “more than 860,000 U.S. soldiers, including more than 108,000 with history of” TBI. The findings were published online July 31 in JAMA Network Open.

Related Links:

— “Rates of new-onset mental health conditions higher in US soldiers with history of TBI,”Robert Herpen, Healio, August 3, 2023

Psychiatric News (8/4) reported, “Suicide is the most common cause of death in patients who have schizophrenia spectrum disorders,” researchers concluded after having “analyzed data from the OPUS I study, a randomized controlled trial of 578 patients experiencing their first episode of psychosis.” The findingswere published online Aug. 1 in the Schizophrenia Bulletin.

Related Links:

— “Suicide Most Common Cause of Death in People With Schizophrenia, Study Finds, Psychiatric News, August 4, 2023

Nexstar (8/5, Suter) reported, “A recent study” published online July 30 in The Lancet Psychiatry “found that by the age of 75 about half of all people will develop a mental” illness. Included in the study were “over 150,000 respondents aged 18 and older from 29 countries between 2001 and 2022.” The study also revealed that “different disorders more commonly” affected “different genders than others.”

HealthDay (8/4, Solomon) reported, “Alcohol use disorder and major depressive disorder were the two most prevalent disorders for male respondents, while major depressive disorder and specific phobia were most prevalent for female respondents,” according to the study.

Related Links:

— “At least half of all people likely to develop mental health disorders before 75: study,”Tara Suter, Nexstar, August 5, 2023

HealthDay (8/3, Murez) reports a rise in cannabis use and progression to cannabis use disorder among non-college young adults post-legalization, according to a study using data from the National Survey on Drug Use and Health. A statement by the study’s co-author encourages continued monitoring of “changes in prevalence of cannabis use, frequent cannabis use and cannabis use disorder among young adults while the cannabis landscape in the U.S. continues to evolve.” The “research doesn’t address why these changes are occurring,” but another co-author suggests changes in public beliefs about cannabis use and increased drug potency might be influencing the trend. The findingswere published in the American Journal of Preventive Medicine.

Related Links:

— “Marijuana Use by Youth: After Legalization, Education Seems to Matter,”Cara Murez, HealthDay, August 3, 2023